BAVARIAN NORDIC
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1992-01-01
- Employees
- 759
- Market Cap
- $3.1B
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 9
- Registration Number
- NCT00485277
- Locations
- 🇺🇸
Alta Bates Herrick Hospital Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 30
- Registration Number
- NCT00390078
- Locations
- 🇩🇪
Charité, Campus Virchow-Klinikum, Berlin, Germany
Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 36
- Registration Number
- NCT00386633
- Locations
- 🇩🇪
LMU-Munich, Department of Infectious Diseases and Tropical Medicine, Munich, Germany
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 581
- Registration Number
- NCT00316589
- Locations
- 🇺🇸
AltaMed Health Services, Los Angeles, California, United States
🇺🇸The CORE Center, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 632
- Registration Number
- NCT00316602
- Locations
- 🇺🇸
Adult & Pediatric Dermatology PC, Overland Park, Kansas, United States
🇺🇸Alta Clinical Research LLC, Tucson, Arizona, United States
🇺🇸Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNEâ„¢) Smallpox Vaccine in Healthy Subjects
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 745
- Registration Number
- NCT00316524
- Locations
- 🇩🇪
Harrison Clinical Research GmbH, Munich, Bavaria, Germany
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-04-21
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 50
- Registration Number
- NCT00189969
- Locations
- 🇩🇪
Focus Clinical Drug Development GmbH, Neuss, Nordrhein, Germany
Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2005-09-19
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 90
- Registration Number
- NCT00189943
- Locations
- 🇩🇪
PharmPlanNet Contract Research GmbH, Moenchengladbach, Germany
An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-10-01
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 77
- Registration Number
- NCT00189930
- Locations
- 🇩🇪
University of Erlangen, Erlangen, Bavaria, Germany
🇩🇪Doctor's Practice, Nürnberg, Bavaria, Germany
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 60
- Registration Number
- NCT00189917
- Locations
- 🇩🇪
Department of Infectious Diseases and Tropical Medicine, Munich, Bavaria, Germany